deltatrials
Terminated PHASE2 NCT02104336

Phase 2 Study of EPI-743 in Children With Pearson Syndrome

An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (VincerinoneTM) in Children With Pearson Syndrome

Sponsor: Edison Pharmaceuticals Inc

Conditions Pearson Syndrome
Interventions EPI-743
Updated 10 times since 2017 Last updated: Nov 16, 2020 Started: Aug 31, 2014 Primary completion: Nov 30, 2015 Completion: Feb 29, 2016

A PHASE2 clinical study on Pearson Syndrome, this trial is terminated or withdrawn. The trial is conducted by Edison Pharmaceuticals Inc and has accumulated 10 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Apr 2022 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Apr 2022 [monthly]

    Terminated PHASE2

  5. Dec 2020 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 5 earlier versions

  1. Sep 2020 — Dec 2020 [monthly]

    Terminated PHASE2

  2. Aug 2018 — Sep 2020 [monthly]

    Terminated PHASE2

  3. Jun 2018 — Aug 2018 [monthly]

    Terminated PHASE2

  4. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Edison Pharmaceuticals Inc
Data source: Edison Pharmaceuticals Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Cleveland, United States
  • • Houston, United States
  • • Orange, United States
  • • Pittsburgh, United States